Biogen (BIIB) Strong In Pre-Market Trading

Trade-Ideas LLC identified Biogen (BIIB) as a pre-market leader candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Biogen

(

BIIB

) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Biogen as such a stock due to the following factors:

  • BIIB has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $425.5 million.
  • BIIB traded 18,485 shares today in the pre-market hours as of 7:35 AM.
  • BIIB is up 5.3% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BIIB with the Ticky from Trade-Ideas. See the FREE profile for BIIB NOW at Trade-Ideas

More details on BIIB:

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. BIIB has a PE ratio of 17. Currently there are 12 analysts that rate Biogen a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for Biogen has been 1.8 million shares per day over the past 30 days. Biogen has a market cap of $57.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.28 and a short float of 1% with 1.62 days to cover. Shares are down 15.2% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Biogen as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • BIOGEN INC has improved earnings per share by 26.9% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, BIOGEN INC increased its bottom line by earning $15.34 versus $12.39 in the prior year. This year, the market expects an improvement in earnings ($18.84 versus $15.34).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Biotechnology industry average. The net income increased by 18.0% when compared to the same quarter one year prior, going from $822.54 million to $970.90 million.
  • BIIB's revenue growth trails the industry average of 19.5%. Since the same quarter one year prior, revenues slightly increased by 6.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.63, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. To add to this, BIIB has a quick ratio of 1.91, which demonstrates the ability of the company to cover short-term liquidity needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...